<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1622178</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2025.1622178</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>Sophora moocroftiana</italic> seeds ethanol extract regulates NLRP3 inflammasome activation and pyroptosis via ROS/TXNIP pathway to amelioration of NAFLD <italic>in vitro</italic> and <italic>in vivo</italic>
</article-title>
<alt-title alt-title-type="left-running-head">Yuan et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1622178">10.3389/fphar.2025.1622178</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Yuan</surname>
<given-names>Ruiying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<xref ref-type="author-notes" rid="fn2">
<sup>&#x2021;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Gui</surname>
<given-names>Mingan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<xref ref-type="author-notes" rid="fn2">
<sup>&#x2021;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Shan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2930379/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ciren</surname>
<given-names>Yangzhen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhuoma</surname>
<given-names>Dongzhi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Guibin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Wendong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Sicen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1481886/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Bin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3054316/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Medicament, College of Medicine, Xizang University</institution>, <addr-line>Lhasa</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Pharmacy, Key Laboratory of Pharmaceutical Research for Metabolic Diseases, Qingdao University of Science and Technology</institution>, <addr-line>Qingdao</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>School of Pharmacy, Health Science Centery, Shaanxi Engineering Research Center of Cardiovascular Drugs Screening and Analysis, Xi&#x2019;an Jiaotong University</institution>, <addr-line>Xi&#x2019;an</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/15167/overview">Michael Heinrich</ext-link>, University College London, United Kingdom</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1375577/overview">Haibo Dong</ext-link>, University of North Carolina at Greensboro, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1454924/overview">Wenfu M. A.</ext-link>, Beijing University of Chinese Medicine, China</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Sicen Wang, <email>wangsc@mail.xjtu.edu.cn</email>; Bin Li, <email>leebin09@qust.edu.cn</email>
</corresp>
<fn fn-type="other" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>ORCID: Ruiying Yuan, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0009-0001-1796-9454">orcid.org/0009-0001-1796-9454</ext-link>Mingan Gui, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0009-0003-0381-0113">orcid.org/0009-0003-0381-0113</ext-link>Wendong Zhang, <ext-link ext-link-type="uri" xlink:href="http://orcid.org/0009-0009-7132-0275">orcid.org/0009-0009-7132-0275</ext-link>
</p>
</fn>
<fn fn-type="equal" id="fn2">
<label>
<sup>&#x2021;</sup>
</label>
<p>These authors have contributed equally to this work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>08</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1622178</elocation-id>
<history>
<date date-type="received">
<day>02</day>
<month>05</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>08</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Yuan, Gui, Huang, Ciren, Zhuoma, Yang, Zhang, Wang and Li.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Yuan, Gui, Huang, Ciren, Zhuoma, Yang, Zhang, Wang and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>
<italic>Sophora moorcroftiana</italic> (Benth.) Baker is a perennial shrub endemic to the Tibetan Plateau. Its seeds are traditional Tibetan medicine for treating jaundice, hepatitis, purulent tonsillitis, diphtheria, and parasitosis.</p>
</sec>
<sec>
<title>Aim of the study</title>
<p>The aim of this research is to explore the possible processes by which the 70% ethanol extract of <italic>S. moocroftiana</italic> seeds (SMS) imparts healing effects in NAFLD what is done by simulating the disease state of NAFLD <italic>via</italic> the creation of a lipid accumulation model in HepG2 cells induced by FFA, and a NAFLD model in C57BL/6J mice induced by HFD.</p>
</sec>
<sec>
<title>Materials and methods</title>
<p>The experiment used HFD fed C57BL/6J mice to establish a NAFLD model, which was divided into a control group, HFD model group, different doses of SMS groups, and a Silymarin group. Were used in the experiment. SMS could improve lipid accumulation, reduce oxidative stress and inflammatory response, which confirmed the improvement effect of SMS on NAFLD. The protective mechanism of SMS on HepG2 cell lipid accumulation model was further verified by qRT-PCR, WB, ELISA, and other methods.</p>
</sec>
<sec>
<title>Results</title>
<p>
<italic>In vitro</italic> and <italic>in vivo</italic> experiments showed that SMS could inhibit ROS and TXNIP dissociation, regulate NLRP3/caspase 1/GSDMD pathway to inhibit pyroptosis, and reduce the release of inflammatory factors such as TNF-&#x3b1;, IL-6, IL-18, and IL-1&#x3b2;, thereby improving the symptoms of lipid accumulation and oxidative stress. These results suggest that SMS can improve NAFLD <italic>via</italic> regulating pyroptosis.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>SMS has promising therapeutic potential in NAFLD management by inhibiting the activation of the NLRP3 inflammasome and pyroptosis via ROS/TXNIP pathway in hepatocytes.</p>
</sec>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="FPHAR_fphar-2025-1622178_wc_abs.tif">
<alt-text content-type="machine-generated">Diagram illustrating the process of liver health, NAFLD, and pyroptosis. It shows pathways involving a healthy liver and NAFLD, influenced by high-fat diet (HFD) in mice, and serum levels. Sophora moorcroftiana reduces inflammation, oxidative stress, and lipid accumulation by affecting pathways involving TXNIP, NLRP3 inflammasome, and cleaved caspase 1. Effects include reduced liver weight, liver index, and membrane pore formation, impacting HepG2 cells and FFA. Pyroptosis and key components like GSDMD-N, TNF-&#x3B1;, and LDH are highlighted.</alt-text>
</graphic>
</p>
</abstract>
<kwd-group>
<kwd>Sophora moocroftiana seeds</kwd>
<kwd>non-alcoholic fatty liver disease</kwd>
<kwd>pyroptosis</kwd>
<kwd>NLRP3 inflammasome</kwd>
<kwd>ROS/TXNIP pathway</kwd>
</kwd-group>
<counts>
<page-count count="17"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Ethnopharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Non-alcoholic fatty liver disease (NAFLD) represents a complex spectrum of hepatic disorders, ranging from excessive fat deposition in the liver to advanced stages involving significant hepatocyte injury, inflammation, and fibrosis. NAFLD is often accompanied by oxidative stress and inflammatory response (<xref ref-type="bibr" rid="B33">Serviddio et al., 2013</xref>; <xref ref-type="bibr" rid="B3">Arrese et al., 2016</xref>). Reactive oxygen species (ROS) generated intracellularly constitute the primary source of oxidative stress. The overproduction of ROS hampers the efficacy of antioxidative defense mechanisms in NAFLD (<xref ref-type="bibr" rid="B2">Anania et al., 2018</xref>). An imbalance between ROS production and the body&#x2019;s antioxidant defense mechanisms can lead to oxidative stress. In NAFLD, excessive lipid accumulation in liver cells leads to increased oxidation of fatty acids in mitochondria and peroxisomes, damaging cellular components, including lipids and proteins. ROS also activates pro-inflammatory signaling pathways that further promote the occurrence and development of oxidative stress in NAFLD (<xref ref-type="bibr" rid="B5">Chen et al., 2020</xref>). ROS have long been recognized as pivotal contributors to pyroptosis, apoptosis, and necroptosis, contributing to various forms of cell demise (<xref ref-type="bibr" rid="B9">Farzanegi et al., 2019</xref>).</p>
<p>Pyroptosis, delineated as a newly acknowledged form of regulated cell death, is characterized by cytoplasmic membrane pore formation, cellular swelling, and rupture, culminating in the release of pro-inflammatory cytokines interleukin-18 (IL-18) and interleukin-1&#x3b2; (IL-1&#x3b2;) (<xref ref-type="bibr" rid="B40">Wang et al., 2020</xref>). Pyroptosis of hepatocytes and the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome it releases play a key role in liver inflammation and fibrosis. It was found in NAFLD patients that after activation of the NLRP3 inflammasome, hepatocytes pyroptosis occurs and releases inflammasome protein, which further drives inflammation and fibrosis reduce liver injury (<xref ref-type="bibr" rid="B12">Gaul et al., 2021</xref>). ROS leads to leading to the dissociation of thioredoxin-interacting protein (TXNIP) from the TXNIP-TRX complex. (<xref ref-type="bibr" rid="B56">Zhou et al., 2010</xref>). TXNIP is a major cellular antioxidant and anti-apoptotic system, which binds to thioredoxin (TRX) and maintains an inactive state (<xref ref-type="bibr" rid="B49">Zhang et al., 2015</xref>). TXNIP is crucial for the activation of NLRP3 inflammasome, and the dissociation of TXNIP from TRX activates NLRP3 (<xref ref-type="bibr" rid="B56">Zhou et al., 2010</xref>). By inhibiting the expression of NLRP3, the occurrence of pyroptosis can be suppressed, thus alleviating the inflammatory response of NAFLD (<xref ref-type="bibr" rid="B32">Ruan et al., 2021</xref>). Gasdermin D (GSDMD) is the execution protein that drives pyroptosis, and the activation of GSDMD is closely related to the activation of NLRP3 inflammasome (<xref ref-type="bibr" rid="B54">Zheng and Kanneganti, 2020</xref>; <xref ref-type="bibr" rid="B45">Yan et al., 2021</xref>). NLRP3 can interact with apoptosis associated speck-like protein containing a caspase recruitment domain (ASC) to cleave Caspase-1 and form mature cleaved caspase-1. GSDMD is specifically cleaved by caspase-1, which can bind in the cellular membrane and form extensive pores, thereby triggering pyroptosis (<xref ref-type="bibr" rid="B34">Shi et al., 2015</xref>; <xref ref-type="bibr" rid="B35">Shi et al., 2017</xref>), as well as releasing pro-inflammatory cytokines such as IL-1&#x3b2; (<xref ref-type="bibr" rid="B22">Liu et al., 2016</xref>). Recent studies have shown that pyroptosis can lead to acute or chronic liver injury (<xref ref-type="bibr" rid="B53">Zhao et al., 2022</xref>) and reducing of hepatocyte pyroptosis has a beneficial effect on NAFLD (<xref ref-type="bibr" rid="B8">Ezquerro et al., 2018</xref>).</p>
<p>
<italic>Sophora moorcroftiana</italic> (Benth.) Baker, a perennial shrub native to the Qinghai-Tibet Plateau, thrives at elevations between 2,900 and 4,100&#xa0;m (<xref ref-type="bibr" rid="B21">Liu et al., 2006</xref>). According to Tibetan medicinal traditions, the seeds of <italic>S. moorcroftiana</italic> are employed in the treatment of jaundice-type hepatitis and are recognized for their anti-inflammatory, antibacterial, detoxifying properties, and other advantageous effects (<xref ref-type="bibr" rid="B26">Luo Y. P. et al., 2018</xref>; <xref ref-type="bibr" rid="B14">Hu et al., 2022</xref>), as well as in combating echinococcosis (<xref ref-type="bibr" rid="B50">Zhang F. et al., 2018</xref>). Previous phytochemical investigations have identified alkaloids, flavonoids, and polysaccharides in this species (<xref ref-type="bibr" rid="B51">Zhang Y. et al., 2018</xref>; <xref ref-type="bibr" rid="B25">Luo Y. et al., 2018</xref>; <xref ref-type="bibr" rid="B36">Shirataki et al., 1988</xref>). Notably, oxymatrine has shown efficacy in reducing lipid accumulation, while matrine addresses mitochondrial dysfunction, accumulation disorders, and inflammation, thereby ameliorating NAFLD (<xref ref-type="bibr" rid="B11">Gao et al., 2018</xref>; <xref ref-type="bibr" rid="B52">Zhang et al., 2020</xref>). In our prior <italic>in vivo</italic> and <italic>in vitro</italic> research, the ethanol extract of <italic>S. moorcroftiana</italic> seeds demonstrated substantial hepatoprotective properties (<xref ref-type="bibr" rid="B48">Yuan et al., 2022</xref>). Despite these findings, investigations into its potential for improving NAFLD remain scarce.</p>
<p>This study aims to investigate how <italic>S</italic>. <italic>moorcroftian</italic>a seeds ameliorate NAFLD by modulating the TXNIP/NLRP3/GSDMD <italic>via</italic> pyroptosis pathway, thereby providing a potential therapeutic strategy for NAFLD treatment.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>2 Materials and methods</title>
<sec id="s2-1">
<title>2.1 Chemicals and reagents</title>
<p>Matrine (&#x2265;98% purity), Sophocarpine (&#x2265;98%), Oxysophocarpine (&#x2265;98%), and Oxymatrine (&#x2265;98%) were obtained from Chengdu Must Bio-Technology Co., Ltd. (Chengdu, China), while the remaining chemicals were sourced from Sigma Chemical Co. (St. Louis, United States). HepG2 cells were cultured in a specialized medium obtained from Procell Life Science &#x26; Technology Co., Ltd. (Wuhan, China). Primary antibodies, including mouse/rabbit anti-TXNIP (DF7506), anti-NLRP3 (BF8029), anti-Caspase 1 (AF5418), anti-cleaved Caspase-1 (AF4005), anti-GSDMD (AF4012), anti-GSDMD-N (DF13758), anti-IL1&#x3b2; (BF8021), and anti-&#x3b2;-actin (AF7018), were procured from Affinity Biopharmaceutical Co., Ltd. (Nanjing, China). Horseradish peroxidase-conjugated goat immunoglobulin G (IgG) (ab150113) and rabbit anti-mouse IgG (ab150077) secondary antibodies were purchased from Abcam Plc. (Cambridge, United Kingdom). Various kits used in the experiment, including triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), superoxide dismutase (SOD), malondialdehyde (MDA), catalase (CAT), glutathione peroxidase (GSH-PX), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AKP) was acquired from Jiancheng Biotechnology Science, Inc. (Nanjing, China). Radioimmunoprecipitation lysis buffer (RIPA), phenylmethanesulfonyl fluoride (PMSF), and Bradford protein assay kits were purchased from Solaibo Technology Co., Ltd. (Beijing, China). The TRIeasy Plus Total RNA Kit reagents were obtained from Enzyme-linked Biotechnology Co., Ltd. (Shanghai, China), while BeyoFast SYBR Green One-Step qRT-PCR Kits were sourced from Beyotime Biotechnology (Shanghai, China). The levels of IL-1&#x3b2;, IL-18, IL-6, and tumor necrosis factor-&#x3b1; (TNF-&#x3b1;) were measured using enzyme-linked immunosorbent assay (ELISA) kits from Boster Biological Technology Co. Ltd. (Wuhan, China).</p>
</sec>
<sec id="s2-2">
<title>2.2 Extraction of <italic>S. moocroftiana</italic> seeds</title>
<p>
<italic>S. moorcroftiana</italic> seeds were purchased from Lhasa in March of 2022 and their authenticity was confirmed by Professor Zhuoma Dongzhi of the College of Medicine at Tibet University in Lhasa, Tibet, China. A sample of the seeds, for which the voucher specimen (No. utibet-1539) was stored in the Herbarium of Herbarium of Department of Medicament, College of Medicine, Tibet University, Lhasa, China. The seeds, which weighed 5,005.1&#xa0;g, were pulverized and extracted with 70% ethanol by refluxing. After filtering and concentrating under reduced pressure, 1,023.1&#xa0;g of extract was obtained (20.44% yield). The extract was preserved in the Component Bank of Tibetan Medicine in Lhasa (No. CBTM-E396), Tibet, China for potential future research purposes.</p>
</sec>
<sec id="s2-3">
<title>2.3 High performance liquid chromatography (HPLC) analysis</title>
<p>Quantitative analysis of the plant metabolites of SMS was carried out utilizing HPLC. In this process, methanol was used to dissolve standard substances containing Matrine, Sophocarpine, Oxysophocarpine, and Oxymatrine at concentrations of 511.0, 170.0, 365.0, and 1,250.5&#xa0;&#x3bc;g/mL, respectively. SMS at a concentration of 3.76&#xa0;mg/mL, was also dissolved in methanol. The separation was performed on an Agilent 5 HC-C18 column (250&#xa0;mm &#xd7; 4.6&#xa0;mm, particle size 5&#xa0;&#x3bc;m) using an LC-2010A HT HPLC system (Shimadzu Corporation, Kyoto, Japan) with HPLC and detection at a wavelength of 210&#xa0;nm. The mobile phase consisted of acetonitrile (A) and a 0.1% aqueous solution of phosphoric acid (B) with a linear gradient elution: 0&#x2013;20&#xa0;min with 3% A, 20&#x2013;45&#xa0;min with 3%&#x2013;15% A, and 45&#x2013;60&#xa0;min with 15% A. The flow rate was maintained at 1.0&#xa0;mL/min, and a 15-min column wash was conducted between injections. After injection, the column was equilibrated with 3% A for 30&#xa0;min. The column temperature was set at 20&#xa0;&#xb0;C, and the injection volume was 5&#xa0;&#x3bc;L. The identification of plant metabolites in SMS was achieved by comparing the retention times of corresponding standard compounds.</p>
</sec>
<sec id="s2-4">
<title>2.4 Experimental animals</title>
<p>Male C57BL/6J mice (weighing 20 &#xb1; 2&#xa0;g) were purchased from the Qingdao Institute for Food and Drug Control (approval number: SYXK (Lu) 2022 0816). These mice were acclimatized to controlled environmental conditions (temperature: 25&#xa0;&#xb0;C &#xb1; 2&#xa0;&#xb0;C, relative humidity: 55% &#xb1; 5%, and a 12/12&#xa0;h light/dark cycle) for a period of 7&#xa0;days, during which they had unrestricted access to food and water. The experimental protocols were ethically approved by the Institutional Animal Care and Use Committee of Qingdao University of Science and Technology (approval number: ACQUST-2020-053).</p>
</sec>
<sec id="s2-5">
<title>2.5 Induction of NAFLD mice and experimental design</title>
<p>The mice were divided into two groups: a control group (CON) with 10 mice and a model group with 50 mice. The CON group received a normal-fat diet comprising 30% wheat, 30% corn, 10% fish, 3% bone meal, and 7% soybean meal. In contrast, the model group was fed a high-fat diet composed of 80% NFD and 20% high-fat feed (containing 3% cholesterol, 7% lard, and egg yolk powder) for 8&#xa0;weeks. Serum levels of TC, TG, ALT, and AST confirmed successful model group establishment using reagent kits. Subsequently, the model group was further divided into five subgroups (n &#x3d; 10 each): the high-fat diet model group (HFD), a positive control group (administered Silymarin at 100&#xa0;mg/kg), and low, medium, and high dosage groups (L: 52&#xa0;mg/kg, M: 104&#xa0;mg/kg, and H:208&#xa0;mg/kg) of the SMS. While the CON and HFD groups received normal saline, the treatment group needed to be given SMS by intragastric administration at a fixed dose every day for 8 weeks. After a 12-h fasting period, blood samples were collected from the orbital vein and centrifuged to obtain serum samples. Liver samples were dissected, weighed, and half of them were stored at &#x2212;80&#xa0;&#xb0;C, while the remaining half was preserved in a 4% polyformaldehyde solution for subsequent experiments.</p>
</sec>
<sec id="s2-6">
<title>2.6 Hematoxylin eosin (H&#x26;E) staining</title>
<p>The liver tissues were fixed in polyformaldehyde, dehydrated, paraffin-embedded, and sectioned to a thickness of 5&#xa0;&#x3bc;m. Subsequently, the sections underwent H&#x26;E staining. Observations were made on these sections under a microscope (Nikon, Tokyo, Japan), and random areas were chosen for photography.</p>
</sec>
<sec id="s2-7">
<title>2.7 Immunohistochemistry assay</title>
<p>Immunohistochemical staining was conducted using 5&#xa0;&#x3bc;m paraffin sections that were dewaxed in xylene. The sections were dehydrated and incubated with 3% H<sub>2</sub>O<sub>2</sub> for 10&#xa0;min, followed by washing with PBS. After blocking with PBS containing 5% fetal bovine serum (FBS), the sections were incubated overnight at 4&#xa0;&#xb0;C with primary antibodies against TXNIP, NLRP3, GSDMD, and IL-6 (1:200). This was followed by incubation with goat anti-rabbit IgG (H &#x2b; L) HRP at 37&#xa0;&#xb0;C. After incubation with Streptavidin-HRP, 2,2&#x2032;-Dimethylbenzidine (DAB) staining was performed, followed by hematoxylin counterstaining. Randomly selected fields were photographed at &#xd7;200 magnification using a light microscope (Nikon, Tokyo, Japan).</p>
</sec>
<sec id="s2-8">
<title>2.8 Cell culture and treatment</title>
<p>HepG2 cells, obtained from Procell Life Science &#x26; Technology Co., Ltd. (Wuhan, China), were cultured in minimum essential medium (MEM) with NEAA supplemented with 10% FBS and 1% penicillin/streptomycin (P/S). The cells were maintained at 37&#xa0;&#xb0;C in a 5% CO<sub>2</sub> conditions, with sub-culturing performed every 2&#x2013;3&#xa0;days. Initially, the HepG2 cells were exposed to varying concentrations of SMS (12.5, 25, 50, and 100&#xa0;&#x3bc;g/mL) for 24&#xa0;h. Then, the cells received an additional treatment with free fatty acid (FFA, 1.0&#xa0;mM) for an extra 24&#xa0;h.</p>
</sec>
<sec id="s2-9">
<title>2.9 Cell viability</title>
<p>Cell viability was evaluated using the MTT assay. HepG2 cells were cultured in a 96-well plate at a concentration of 6 &#xd7; 10&#x5e;5 cells/mL (100&#xa0;&#x3bc;L). The cells were exposed to SMS either alone or at varying concentrations (12.5, 25, 50, and 100&#xa0;&#x3bc;g/mL), for 24&#xa0;h. Additionally, the cells received an extra treatment with FFA (Sodium oleate (OA) and sodium palmitate (PA) were dissolved in a 20% bovine serum albumin (BSA) solution and mixed at a ratio of 2:1, 1.0&#xa0;mM) for an additional 24&#xa0;h. Subsequently, a solution of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, 2.5&#xa0;mg/mL, 50&#xa0;&#x3bc;L) was added to each well. After a 4-h incubation, formazan crystals were dissolved in Dimethyl sulfoxide (DMSO), and the optical density (OD) was measured at a wavelength of 490&#xa0;nm. The initial OD was recorded at the time of compound addition.</p>
</sec>
<sec id="s2-10">
<title>2.10 ROS fluorescence probe detection</title>
<p>HepG2 cells were cultured in a 6-well plate at a concentration of 6 &#xd7; 10&#x5e;5 cells/mL (1&#xa0;mL). Detection of ROS was conducted utilizing an ROS Assay Kit, following the manufacturer&#x2019;s protocol. Diluted DCFH-DA (1:1,000) was added to each well, and the cells were incubated at 37&#xa0;&#xb0;C for 20&#xa0;min in a cell culture incubator. After incubation, the cells were wished thrice with cell culture medium, and fluorescence was visualized using a laser confocal microscope (Olympus Corporation DP74, Tokyo, Japan).</p>
</sec>
<sec id="s2-11">
<title>2.11 Oil red O staining</title>
<p>To evaluate lipid accumulation in liver tissue and HepG2 cells, liver sections underwent fixation using 4% formaldehyde and subsequent staining with Oil Red O. After isopropanol washing, the sections were counterstained with hematoxylin and examined using a microscope (Olympus Corporation DP74, Tokyo, Japan). HepG2 cells were stained using the Oil Red O kit designed for cultured cells (Solarbio, Beijing, China). Random areas were selected for photographic documentation via light microscopy (Olympus BX53, Tokyo, Japan).</p>
</sec>
<sec id="s2-12">
<title>2.12 Western blot (WB) analysis</title>
<p>Protein specimens were initially gathered from HepG2 cells and the liver tissues of mice. The isolation procedure utilized RIPA buffer, supplemented with 1% PMSF. The Bradford protein assay kit was used to quantify the protein quantities. Following this, protein samples of equal amounts were differentiated using 10%&#x2013;15% Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). These were then transferred onto NC membranes. The membranes were treated with 5% skim milk in TBST for a duration of 2&#xa0;h at room temperature. Primary antibodies specific were applied to the membranes for 1.5&#xa0;h at room temperature. After washing the membranes thrice with TBST, secondary antibodies were introduced for 1&#xa0;h at room temperature. The protein bands were visualized using an Enhanced chemiluminescence kit (ECL). A ChemiDoc image analyzer (Tanon 4,600, Shanghai, China) was used to ascertain protein concentrations, and ImageJ software (NIH, Bethesda, MD, United States) was utilized for image analysis and manipulation.</p>
</sec>
<sec id="s2-13">
<title>2.13 RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR)</title>
<p>The process of isolating RNA from HepG2 cells utilized the TRIeasy Plus Total RNA Kit. This was followed by reverse transcription and qRT-PCR, facilitated by the BeyoFast SYBR Green One-Step qRT-PCR Kit, to measure the mRNA levels of TNF-&#x3b1;, IL-6, IL-18, IL-1&#x3b2;, and TXNIP. &#x3b2;-actin mRNA served as a control in these experiments. The entire procedure was repeated three times, and the Livak method was used to assess mRNA expression levels. &#x394;Ct represents the difference between the Ct value of the target gene and the Ct value of the reference gene. &#x394;&#x394;Ct&#x200b; is the difference between the &#x394;Ct values of the experimental groups and those of the control group. The primer sequences are provided in <xref ref-type="table" rid="T1">Table 1</xref>.<disp-formula id="equ1">
<mml:math id="m1">
<mml:mrow>
<mml:mi>m</mml:mi>
<mml:mi>R</mml:mi>
<mml:mi>N</mml:mi>
<mml:mi>A</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi>e</mml:mi>
<mml:mi>x</mml:mi>
<mml:mi>p</mml:mi>
<mml:mi>r</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>s</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>n</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi>l</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>s</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:msup>
<mml:mn>2</mml:mn>
<mml:mrow>
<mml:mo>&#x2212;</mml:mo>
<mml:mo>&#x394;</mml:mo>
<mml:mo>&#x394;</mml:mo>
<mml:msub>
<mml:mi>C</mml:mi>
<mml:mi>t</mml:mi>
</mml:msub>
</mml:mrow>
</mml:msup>
<mml:mrow>
<mml:mfenced open="(" close=")" separators="|">
<mml:mrow>
<mml:mi>L</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>v</mml:mi>
<mml:mi>a</mml:mi>
<mml:mi>k</mml:mi>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mtext>&#x2009;</mml:mtext>
<mml:mi>m</mml:mi>
<mml:mi>e</mml:mi>
<mml:mi>t</mml:mi>
<mml:mi>h</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>d</mml:mi>
</mml:mrow>
</mml:mfenced>
</mml:mrow>
</mml:mrow>
</mml:math>
</disp-formula>
</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>List of primers for qRT-PCR.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Target</th>
<th align="left">Primer sequences (forward)</th>
<th align="left">Primer sequences (reverse)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">IL-6</td>
<td align="left">ACC&#x200b;ACT&#x200b;CCC&#x200b;AAC&#x200b;AGA&#x200b;CCT&#x200b;GTC&#x200b;T</td>
<td align="left">CAG&#x200b;ATT&#x200b;GTT&#x200b;TTC&#x200b;TGC&#x200b;AAG&#x200b;TGC&#x200b;AT</td>
</tr>
<tr>
<td align="left">TNF-&#x3b1;</td>
<td align="left">ACA&#x200b;AGG&#x200b;CTG&#x200b;CCC&#x200b;CGA&#x200b;CTA&#x200b;C</td>
<td align="left">TGG&#x200b;GCT&#x200b;CAT&#x200b;ACC&#x200b;AGG&#x200b;GTT&#x200b;TG</td>
</tr>
<tr>
<td align="left">IL-18</td>
<td align="left">GAC&#x200b;TCT&#x200b;TGC&#x200b;GTC&#x200b;AAC&#x200b;TTC&#x200b;AAG&#x200b;G</td>
<td align="left">CAG&#x200b;GCT&#x200b;GTC&#x200b;TTT&#x200b;TGT&#x200b;CAA&#x200b;CGA</td>
</tr>
<tr>
<td align="left">IL-1&#x3b2;</td>
<td align="left">CTT&#x200b;TCC&#x200b;CGT&#x200b;GGA&#x200b;CCT&#x200b;TCC&#x200b;A</td>
<td align="left">CTC&#x200b;GGA&#x200b;GCC&#x200b;TGT&#x200b;AGT&#x200b;GCA&#x200b;GTT</td>
</tr>
<tr>
<td align="left">TXNIP</td>
<td align="left">AGC&#x200b;CAA&#x200b;CTC&#x200b;AAG&#x200b;AGG&#x200b;CAA&#x200b;AG</td>
<td align="left">GAG&#x200b;ACT&#x200b;GAC&#x200b;ACA&#x200b;CGT&#x200b;CCA&#x200b;TC</td>
</tr>
<tr>
<td align="left">&#x3b2;-actin</td>
<td align="left">GGC&#x200b;TGT&#x200b;ATT&#x200b;CCC&#x200b;CTC&#x200b;CAT&#x200b;CG</td>
<td align="left">CCA&#x200b;GTT&#x200b;GGT&#x200b;AAC&#x200b;AAT&#x200b;GCC&#x200b;ATG&#x200b;T</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-14">
<title>2.14 Biochemical analysis</title>
<p>The lipid deposition was detected by measuring the levels of TG, TC, LDL-C, HDL-C in both serum and HepG2 cells using a reagent kit. Oxidative stress was detected by measuring the levels of SOD, CAT, GSH-PX and the activity of MDA in both serum and HepG2 cells using a reagent kit. Liver function was assessed by measuring the levels of AST, ALT, and AKP in serum using reagent kits. The levels of IL-1&#x3b2; and IL-18 in serum homogenates and HepG2 cells, as well as IL-6 and TNF-&#x3b1; in liver tissues were detected using ELISA kits. Additionally, the mRNA levels of TNF-&#x3b1;, IL-6, IL-18, and IL-1&#x3b2; in HepG2 cells were determined using qRT-PCR, as mentioned earlier.</p>
</sec>
<sec id="s2-15">
<title>2.15 Immunofluorescence assay</title>
<p>The HepG2 cells, after appropriate preparation, were rinsed with PBS and then fixed with 4% paraformaldehyde for 30&#xa0;min. Subsequently, the cells were treated with 0.1% Triton X-100 for 10&#xa0;min and then blocked using a solution of PBS containing 5% FBS at ambient temperature for another 30&#xa0;min. The primary antibody was applied and allowed to incubate overnight at 4&#xa0;&#xb0;C. This was followed by an incubation period with FITC-conjugated goat anti-mouse IgG or rabbit anti-rabbit IgG secondary antibody at room temperature for 1&#xa0;h, in conjunction with a 5-min incubation with DAPI. The immunostaining was then observed using a fluorescence microscope (Olympus Corporation DP74, Tokyo, Japan).</p>
</sec>
<sec id="s2-16">
<title>2.16 Scanning electron microscopy (SEM)</title>
<p>The HepG2 cells, after appropriate preparation, were washed with PBS to remove the culture medium and then fixed with 5% glutaraldehyde for 1&#xa0;h at room temperature. Post the glutaraldehyde exposure, gradient concentrations of ethanol were successively dehydrated for 15&#xa0;min. The samples were then subjected to a 12-h freeze-drying period in a vacuum freeze-dryer. Pretreatment steps were performed on the cells using ion sputter coating technology to stabilize the cell surface and mitigate charge effects. The structure of the cell membrane was then examined by SEM.</p>
</sec>
<sec id="s2-17">
<title>2.17 Cell transfection with small interfering RNA (siRNA) targeting TXNIP</title>
<p>In order to investigate the relationship between TXNIP and pyroptosis, HepG2 cells were transfected with TXNIP-siRNA, procured from GenePharma Co., Ltd. (Suzhou, China), in accordance with the instructions provided by the manufacturer. The transfection process was initiated when the cell density was within the range of 60%&#x2013;80%. After transfection, the cells were incubated at 37&#xa0;&#xb0;C for a duration of 4&#x2013;6&#xa0;h, following which they were transferred to complete culture medium. The expression of mRNA was examined within a period of 24&#x2013;72&#xa0;h, while protein expression was analyzed within a timeframe of 48&#x2013;96&#xa0;h.</p>
</sec>
<sec id="s2-18">
<title>2.18 Statistical analysis</title>
<p>The experimental data underwent analysis using GraphPad Prism 7 software, developed by GraphPad Software in San Diego, CA, United States of America. The data were presented as mean &#xb1; Standard deviation (SD). For continuous data, a one-way ANOVA was applied, followed by Tukey&#x2019;s <italic>post hoc</italic> test for inter-group comparisons. Statistical significance is indicated as <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01, <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 and <sup>&#xa7;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#xa7;&#xa7;</sup>
<italic>P</italic> &#x3c; 0.01.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>3 Results</title>
<sec id="s3-1">
<title>3.1 Quantitative analysis of the four ingredients in SMS identified by HPLC</title>
<p>The HPLC spectra representative of SMS are shown in <xref ref-type="fig" rid="F1">Figure 1B</xref>. The primary constituents of SMS are detailed in <xref ref-type="table" rid="T2">Table 2</xref>. The chemical formulas for Matrine, Sophocarpine, Oxysophocarpine, and Oxymatrine are illustrated in <xref ref-type="fig" rid="F1">Figure 1</xref>. As per the regression equation of the curve, the concentrations of Matrine, Sophocarpine, Oxysophocarpine, and Oxymatrine in <italic>S. moorcroftiana</italic> seeds are 8.26, 1.41, 3.59, and 45.89&#xa0;mg/g, respectively.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>The representative ingredients in SMS were analyzed by HPLC. <bold>(A)</bold> The chemical structure of Matrine, Sophocarpine, Oxysophocarpine and Oxymatrine and <bold>(B)</bold> chromatograms of four plant metabolites in reference substances and SMS.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g001.tif">
<alt-text content-type="machine-generated">Chemical structures of Matrine, Oxymatrine, Sophocarpine, and Oxysophocarpine are shown above a chromatogram. The chromatogram displays peaks for these compounds at different retention times. Peaks are labeled: Matrine, Sophocarpine, Oxysophocarpine, and Oxymatrine. The vertical axis represents absorption in milli-Absorbance units (mAu), and the horizontal axis represents time in minutes. SMS is indicated for a baseline measurement.</alt-text>
</graphic>
</fig>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Preliminary identification of compounds and content determination in SMS.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Compound name</th>
<th align="left">Molecular formula</th>
<th align="left">R.T. (min)</th>
<th align="left">Curve regression equations</th>
<th align="left">R<sup>2</sup>
</th>
<th align="left">Linear range (&#x3bc;g/mL)</th>
<th align="left">Content (mg/g)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Matrine</td>
<td align="left">C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O</td>
<td align="left">13.04</td>
<td align="left">Y &#x3d; 9,250,264.11 X - 27,270.73</td>
<td align="left">0.9996</td>
<td align="left">51.1&#x2013;511.0</td>
<td align="left">8.26</td>
</tr>
<tr>
<td align="left">Sophocarpine</td>
<td align="left">C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O</td>
<td align="left">18.29</td>
<td align="left">Y &#x3d; 12,170,176.15 X - 21,157.64</td>
<td align="left">0.9995</td>
<td align="left">17.0&#x2013;170.0</td>
<td align="left">1.41</td>
</tr>
<tr>
<td align="left">Oxysophocarpine</td>
<td align="left">C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O<sub>2</sub>
</td>
<td align="left">23.93</td>
<td align="left">Y &#x3d; 10,639,731.88 X - 28,282.10</td>
<td align="left">0.9996</td>
<td align="left">36.5&#x2013;365.0</td>
<td align="left">3.59</td>
</tr>
<tr>
<td align="left">Oxymatrine</td>
<td align="left">C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>
</td>
<td align="left">25.49</td>
<td align="left">Y &#x3d; 3,986,402.89 X - 26,149.87</td>
<td align="left">0.9996</td>
<td align="left">125.1&#x2013;1,250.5</td>
<td align="left">45.89</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3-2">
<title>3.2 SMS restored on liver injury of NAFLD in HFD fed C57BL/6J mice</title>
<p>The effect of SMS on improving accumulation of lipids was confirmed by evaluating liver histopathology. Liver histopathology revealed significant hepatic injury in the HFD group compared to the CON group. However, H&#x26;E staining indicated orderly ordering of hepatocytes and reduced fat infiltration after SMS treatment (<xref ref-type="fig" rid="F2">Figure 2B</xref>). After 8&#xa0;weeks of treatment, a significant decrease in liver weight and index was observed in the SMS group (<xref ref-type="fig" rid="F2">Figures 2C,D</xref>). Treatment with SMS also reduced the levels of ALT, AST, and AKP compared to the FFA group in a dose-dependent manner,The levels of ALT, AST and AKP in L, M and H groups were significantly affected (<xref ref-type="fig" rid="F2">Figures 2E&#x2013;G</xref>). Collectively, these findings suggest that SMS exhibits a protective effect against liver injury of NAFLD <italic>in vivo</italic>.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Effect of SMS on hepatic injury of NAFLD in HFD-fed C57BL/6J mice. <bold>(A)</bold> Experimental procedure of mice. <bold>(B)</bold> H&#x26;E staining were performed on liver tissue sections of each mice and a representative image of one mice per group has been displayed (200 &#xd7;), The levels of <bold>(C)</bold> liver weight and <bold>(D)</bold> index. Serum <bold>(E)</bold> ALT, <bold>(F)</bold> AST and <bold>(G)</bold> AKP were detected by reagent kits. Silymarin (100&#xa0;mg/kg) was used as the positive control. Results are mean &#xb1; SD (n &#x3d; 10). <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. HFD group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g002.tif">
<alt-text content-type="machine-generated">Diagram displaying an experimental setup and results. Panel A shows a timeline for groups of mice: Group 1 (control), Group 2 (high-fat diet), Groups 3-5 (NAFLD with varying doses of SMS), and Group 6 (Silymarin treatment). Panel B presents liver histology images for each group showing differences in cellular structures. Panels C-G are bar charts comparing liver weight, liver index, and serum levels of ALT, AST, and AKP across the groups. Groups treated with SMS or Silymarin show different levels compared to the control and high-fat diet groups.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-3">
<title>3.3 SMS alleviate lipid deposition of NAFLD in HFD fed C57BL/6J mice</title>
<p>Lipid accumulation plays a significant role in the initiation and progression of liver injury in NAFLD. Oil Red O staining demonstrated a notable increase in orange lipid droplets in the group subjected to HFD. Subsequently, the abundance of these lipid droplets decreased upon treatment with varying concentrations of SMS. The quantitative analysis of Oil Red O staining results indicated a significant reduction in orange lipid droplets with increasing drug concentration (<xref ref-type="fig" rid="F3">Figures 3A,B</xref>). In addition, SMS treatment effectively inhibited the levels of TC, TG, and LDL-C in H group compared to HFD (<xref ref-type="fig" rid="F3">Figures 3C&#x2013;E</xref>). Furthermore, SMS treatment led to an elevation in HDL-C levels (<xref ref-type="fig" rid="F3">Figure 3F</xref>). In conclusion, SMS administration alleviated hepatic lipid deposition <italic>in vivo</italic>.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Effect of SMS on lipid accumulation of NAFLD in HFD-fed C57BL/6J mice. <bold>(A)</bold> Oil red O staining was performed on liver tissue sections of each mice. Representative images of one mice per group has been displayed by light microscope (400 &#xd7;). <bold>(B)</bold> The quantification statistical result of Oil Red O staining. The levels of serum <bold>(C)</bold> TC, <bold>(D)</bold> TG, <bold>(E)</bold> LDL-C and <bold>(F)</bold> HDL-C were detected by reagent kits. Silymarin (100&#xa0;mg/kg) was used as the positive control. Results are mean &#xb1; SD (n &#x3d; 10). <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. HFD group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g003.tif">
<alt-text content-type="machine-generated">Histological liver sections and bar graphs analyze lipid accumulation and serum lipid profiles. Panel A shows Oil Red O staining with varying lipid content. Panels B to F display bar graphs quantifying Oil Red O, serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) across different treatments, including control (CON), high-fat diet (HFD), and silymarin. Scale bars indicate 100 micrometers.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-4">
<title>3.4 SMS inhibit oxidative stress and inflammation of NAFLD in HFD fed C57BL/6J mice</title>
<p>Oxidative stress and inflammation play a significant role in both the onset and progression of liver injury in NAFLD (<xref ref-type="bibr" rid="B17">Li J. et al., 2021</xref>). The MDA activity increased in the HFD group and diminished after SMS treatment. Furthermore, the levels of SOD and GSH-Px exhibited a notable rise compared to the HFD group (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>). Compared with HFD group, SMS treatment resulted in dose-dependent inhibition of expression levels of TNF-&#x3b1;, IL-6, IL-18, and IL-1&#x3b2;, with significant improvement in group H (<xref ref-type="fig" rid="F4">Figures 4D&#x2013;G</xref>). In conclusion, these findings indicate that SMS mitigates liver oxidative stress and inflammation <italic>in vivo</italic>.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Effects of SMS on oxidative stress and inflammation of NAFLD in HFD-fed C57BL/6J mice. The levels of serum <bold>(A)</bold> MDA, <bold>(B)</bold> SOD, <bold>(C)</bold> GSH-Px, <bold>(D)</bold> IL-18, <bold>(E)</bold> IL-1&#x3b2;, <bold>(F)</bold> TNF-&#x3b1; and <bold>(G)</bold> IL-6 were determined by reagent kits. Were determined by reagent kits. Silymarin (100&#xa0;mg/kg) was used as the positive control. Results are mean &#xb1; SD (n &#x3d; 10). <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. HFD group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g004.tif">
<alt-text content-type="machine-generated">Bar graphs A to G compare serum markers across different conditions: CON, HFD, L, M, H, and Silymarin. A shows MDA levels, B shows SOD, C shows GSH-PX, D shows IL-18, E shows IL-1&#x3B2;, F shows TNF-&#x3B1;, and G shows IL-6. Notable differences are marked with symbols indicating statistical significance.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-5">
<title>3.5 SMS inhibit pyroptosis via TXNIP/NLRP3 pathway in HFD fed C57BL/6J mice</title>
<p>The impact of SMS on pyroptosis was assessed by analyzing snap-frozen liver tissue sections from mice via IHC for TXNIP, NLRP3, GSDMD, and IL-1&#x3b2; (<xref ref-type="fig" rid="F5">Figure 5</xref>). The staining indicated that SMS treatment led to a dose-dependent reduction in the levels of TXNIP, NLRP3, GSDMD, and IL-1&#x3b2; compared to the HFD group. Overall, the SMS extract suppresses pyroptosis in non-alcoholic fatty liver disease through the TXNIP/NLRP3 pathway.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Effect of SMS on TXNIP/NLRP3 pathway of pyroptosis in HFD-fed C57BL/6J mice. Snap frozen liver tissue sections of mice were analyzed by IHC for TXNIP, NLRP3, GSDMD and IL-1&#x3b2; and a representative image of mice per group has been displayed (200&#xd7;). Silymarin (100&#xa0;mg/kg) was used as the positive control.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g005.tif">
<alt-text content-type="machine-generated">Microscopic images displaying liver tissue sections stained for markers TXNIP, NLRP3, GSDMD, and IL-1&#x3B2; across different treatment groups: CON, HFD, SMS at low (L), medium (M), and high (H) doses, and Silymarin. The sections show varying intensities of brown staining, indicating different levels of each marker expression among the groups.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-6">
<title>3.6 SMS alleviate lipid deposition in FFA induced HepG2 cells</title>
<p>In cell experiments, SMS (200&#xa0;&#x3bc;g/mL) significantly inhibited cell proliferation (<xref ref-type="fig" rid="F6">Figure 6A</xref>). However, SMS at lower concentrations had no effect on cell proliferation. Consequently, subsequent studies will use concentrations of SMS ranging from 12.5 to 100&#xa0;&#x3bc;g/mL. Established <italic>in vitro</italic> lipid deposition cell culture model using FFA treatment in HepG2 cells FFA treatment group. The results showed that significantly elevated expression levels of TG, TC, and LDL-C in the FFA group were reversed by SMS in a dose-dependent manner, and concentrations of 50 and 100&#xa0;&#x3bc;g/mL were significantly improved (<xref ref-type="fig" rid="F6">Figures 6B&#x2013;D</xref>). Additionally, treatment with SMS increased levels of HDL-C (<xref ref-type="fig" rid="F6">Figure 6E</xref>). Oil Red O staining showed that there were obvious orange lipid droplets increased in the FFA treatment group compared to the CON group (<xref ref-type="fig" rid="F6">Figure 6F</xref>). However, orange lipid droplets were decreased after treated with various concentrations SMS. Taken together, these results indicate that SMS reduces lipid deposition <italic>in vitro</italic>.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Effects of SMS on lipid accumulation in FFA induced HepG2 cells. Cells were treated with different concentrations of SMS (12.5&#xa0;&#x3bc;g/mL-100&#xa0;&#x3bc;g/mL) and then induced with FFA (1&#xa0;mM) for 24&#xa0;h each. <bold>(A)</bold> Cell viability was evaluated by MTT assay. The levels of <bold>(B)</bold> TC, <bold>(C) </bold>TG, <bold>(D)</bold> LDL-C and <bold>(E)</bold> HDL-C were detected by reagent kits. <bold>(F)</bold> Oil red O staining was performed on HepG2 cells and displayed by light microscope (200&#xd7;). Results are mean &#xb1; SD. (n &#x3d; 3) <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. FFA group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g006.tif">
<alt-text content-type="machine-generated">Graphs A to E show the effects of varying SMS concentrations on cell viability, total cholesterol, triglycerides, LDL-C, and HDL-C, with significant changes marked. Image F shows Oil Red O staining under different conditions: CON, FFA, and various SMS concentrations (12.5, 25, 50, 100 &#xB5;g/mL), with visible differences in lipid accumulation.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-7">
<title>3.7 SMS alleviate liver oxidative stress and inflammation in FFA induced HepG2 cells</title>
<p>To further confirm the antioxidative and anti-inflammatory effects of SMS. The antioxidative effect of SMS was assessed by evaluating intracellular ROS levels through fluorescence staining. Treatment with SMS following FFA induction significantly mitigated ROS levels in HepG2 cells (<xref ref-type="fig" rid="F7">Figure 7A</xref>). Furthermore, the antioxidative impact of SMS was validated by evaluating the levels of the lipid peroxidation product (MDA) and antioxidant enzymes (CAT, SOD, and GSH-Px) using assay kits. Concordant with the intracellular ROS levels, MDA concentrations increased in the FFA group and decreased following SMS administration. Moreover, the levels of CAT, SOD, and GSH-Px were significantly elevated compared to the FFA group (<xref ref-type="fig" rid="F7">Figures 7B&#x2013;E</xref>). The anti-inflammatory effect of SMS was examined using qRT-PCR. Treatment with SMS in a dose-dependent manner suppressed the expression of TNF-&#x3b1;, IL-6, IL-18, and IL-1&#x3b2; mRNA in comparison to the FFA group (<xref ref-type="fig" rid="F7">Figures 7F&#x2013;I</xref>). Collectively, these findings demonstrate that SMS mitigates oxidative stress and inflammation <italic>in vitro</italic>.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Effect of SMS on liver oxidative stress and inflammation in FFA induced HepG2 cells. Cells were treated with different concentrations of SMS (12.5&#xa0;&#x3bc;g/mL-100&#xa0;&#x3bc;g/mL) and then induced with FFA (1&#xa0;mM) for 24&#xa0;h each. <bold>(A)</bold> The fluorescence intensity of ROS was detected by immunofluorescence staining. The levels of <bold>(B)</bold> MDA, <bold>(C)</bold> CAT, <bold>(D)</bold> SOD and <bold>(E)</bold> GSH-Px were detected by reagent kits. The levels of <bold>(F)</bold> TNF-&#x3b1;, <bold>(G)</bold> IL-6, <bold>(H)</bold> IL-18 and <bold>(I)</bold> IL-1&#x3b2; mRNA expression were detected by qRT-PCR. Results are mean &#xb1; SD. (n &#x3d; 3) <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. FFA group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g007.tif">
<alt-text content-type="machine-generated">A series of graphs displaying experimental results under different conditions. Panel A shows images of samples labeled CON, FFA, and multiple SMS concentrations (12.5 to 100 &#xB5;g/mL). Panels B to I are bar graphs representing various biochemical measurements: MDA, CAT, SOD, GSH-PX, TNF-&#x3B1; mRNA level, IL-6 mRNA level, IL-18 mRNA level, and IL-1&#x3B2; mRNA level under FFA and SMS treatments. Bars indicate changes in values as SMS concentration increases, with statistical significance marked by symbols such as `##` and `**`.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-8">
<title>3.8 SMS inhibit release of inflammatory factors in FFA induced HepG2 cells</title>
<p>To determine the protective effect of SMS on cell injury induced by FFA. Cell viability significantly increased compared with FFA group (<xref ref-type="fig" rid="F8">Figure 8A</xref>), indicating the protective effect of SMS on FFA-induced HepG2 cells. The morphology of FFA cultured HepG2 cells was compared using SEM. The results showed that the surface of cell membrane in the CON group remained intact. FFA group exhibited a lot of membrane pores, while the SMS (100&#xa0;&#x3bc;g/mL) group showed a significant reduction in the number of membrane pores compared to the FFA group (<xref ref-type="fig" rid="F8">Figure 8B</xref>). Assessed the effect of SMS on release of maker of pyroptosis (Lactate dehydrogenase, LDH) and inflammatory factors (IL-18, IL-1&#x3b2;). Treatment with SMS inhibited the levels of LDH, IL-18, and IL-1&#x3b2; compared to the FFA group in a dose-dependent manner (<xref ref-type="fig" rid="F8">Figures 8C&#x2013;E</xref>). Taken together, these results indicate that reduce the number of membrane pores and release of inflammatory factors <italic>in vitro</italic>.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Effect of SMS on release of inflammatory factors in FFA induced HepG2 cells. Cells were treated with different concentrations of SMS (12.5&#xa0;&#x3bc;g/mL-100&#xa0;&#x3bc;g/mL) and then induced with FFA (1&#xa0;mM) for 24&#xa0;h each. <bold>(A)</bold> Cell viability was evaluated by MTT assay. <bold>(B)</bold> Representative SEM images (40 or 200&#xd7;). The levels of <bold>(C)</bold> LDH, <bold>(D)</bold> IL-1&#x3b2; and <bold>(E)</bold> IL-18 were detected by reagent kits. Results are mean &#xb1; SD (n &#x3d; 3). <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. FFA group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g008.tif">
<alt-text content-type="machine-generated">Composite image of five figures showing results of a scientific study. Panel A shows a bar graph of cell viability (%) with various concentrations of SMS and FFA. Panel B displays microscopic images at 40x and 200x magnifications for control, FFA, and SMS conditions, highlighting structural differences. Panel C illustrates a bar graph of LDH levels (U/L), and panels D and E show bar graphs of IL-1&#x3B2; and IL-18 levels (pg/mL), respectively, with varying SMS concentrations. All graphs show trends of increasing or decreasing levels depending on the treatments, with asterisks indicating statistical significance.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-9">
<title>3.9 SMS inhibit pyroptosis via TXNIP/NLRP3 pathway in FFA induced HepG2 cells</title>
<p>To investigate the impact of SMS on pyroptosis, HepG2 cells induced by FFA were exposed to varying concentrations of SMS and subsequently subjected to immunofluorescence staining (<xref ref-type="fig" rid="F9">Figures 9A&#x2013;C</xref>). Representative images from each group confirmed that SMS alleviated NAFLD by inhibiting pyroptosis, the levels of TXNIP, NLRP3, and GSDMD proteins were upregulated, and this escalation was mitigated by SMS. qRT-PCR findings revealed a dose-dependent inhibition of TXNIP mRNA expression following SMS treatment compared to the FFA group (<xref ref-type="fig" rid="F9">Figure 9D</xref>). Western blot analysis demonstrated that the markedly elevated expression levels of TXNIP, NLRP3, caspase 1, cleaved-caspase 1, and pyroptosis-related proteins in the FFA group were dose-dependently reversed by SMS (<xref ref-type="fig" rid="F9">Figure 9E</xref>). In addition, studies on the active compounds of SMS have shown that four alkaloids can effectively reduce the expression of LDH and have a certain anti-pyroptosis effect (<xref ref-type="sec" rid="s12">Supplementary Figure S1A&#x2013;C</xref>). These results collectively indicate that SMS suppresses pyroptosis via the TXNIP/NLRP3 pathway <italic>in vitro</italic>.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Effect of SMS on TXNIP/NLRP3 pathway in FFA induced HepG2 cells. Cells were treated with different concentrations of SMS and then induced with FFA (1&#xa0;mM) for 24&#xa0;h each. <bold>(A&#x2013;C)</bold> The fluorescence intensity of TXNIP, NLRP3 and GSDMD was detected by immunofluorescence staining. The green color represented TXNIP, NLRP3 and GSDMD staining. <bold>(D)</bold> The levels of TXNIP mRNA expression were detected by qRT-PCR. <bold>(E)</bold> The expression of TXNIP, NLRP3, caspase 1, cleaved-caspase 1, GSDMD and GSDMD-N were detected by Western blotting, and their expression was normalized relative to &#x3b2;-actin. Results are mean &#xb1; SD (n &#x3d; 3). <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. FFA group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g009.tif">
<alt-text content-type="machine-generated">Fluorescence microscopy images and graphs depicting cellular responses. Panels A, B, and C show TXNIP, NLRP3, and GSDMD expression with DAPI-stained nuclei under different FFA and SMS treatments. Panel D presents bar graphs illustrating TXNIP mRNA levels and expression ratios, while panel E includes a Western blot analysis of proteins like NLRP3 and GSDMD under various conditions, highlighting changes in protein expression in response to treatments.</alt-text>
</graphic>
</fig>
</sec>
<sec id="s3-10">
<title>3.10 SMS inhibits inflammatory damage by regulating pyroptosis mediated via TXNIP in FFA induced HepG2 cells</title>
<p>HepG2 cells were subjected to TXNIP silencing using siRNA to assess its impact on pyroptosis. The findings exhibited successful delivery of siRNA-TXNIP into HepG2 cells, resulting in decreased levels of TXNIP mRNA and protein (<xref ref-type="fig" rid="F10">Figures 10A&#x2013;C</xref>). The silencing of TXNIP significantly reduced the expression of TC, TG, IL-18, and IL-1&#x3b2; in FFA-induced HepG2 cells compared to the Con group, and the therapeutic effect of SMS was abolished (<xref ref-type="fig" rid="F10">Figures 10D,E</xref>). These outcomes indicate that SMS attenuates the expression of inflammatory markers and mitigates lipid accumulation by suppressing TXNIP expression.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>Effect of SMS on the inflammation in FFA induced TXNIP knockdown HepG2 cells. <bold>(A)</bold> The protein level of TXNIP were detected by Western blotting with siRNA-TXNIP. <bold>(B)</bold> Cells were treated with SMS (100&#xa0;&#x3bc;g/mL) and then induced with FFA (1&#xa0;mM) for 24&#xa0;h each. The levels of TXNIP mRNA expression were determined by qRT-PCR. The levels of <bold>(C)</bold> LDH, <bold>(D)</bold> IL-1&#x3b2;, <bold>(E)</bold> IL-18, <bold>(F)</bold> TC and <bold>(G)</bold> TG were detected by reagent kits. Results are mean &#xb1; SD (n &#x3d; 3). <sup>&#x23;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>P</italic> &#x3c; 0.01 vs. siR-Control group; <sup>&#xa7;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#xa7;&#xa7;</sup>
<italic>P</italic> &#x3c; 0.01 vs. CON group; <sup>&#x2a;</sup>
<italic>P</italic> &#x3c; 0.05, <sup>&#x2a;&#x2a;</sup>
<italic>P</italic> &#x3c; 0.01 vs. FFA group.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g010.tif">
<alt-text content-type="machine-generated">Grouped bar charts and a Western blot image showing the effects of SMS, siR-Control, and siR-TXNIP on various parameters. Panel A displays TXNIP protein levels via Western blot with a graph of TXNIP/&#x3B2;-actin ratio. Panels B to G show bar graphs for TXNIP mRNA level, LDH, IL-1&#x3B2;, IL-18, TC, and TG levels under different conditions, with statistical annotations indicating significance.</alt-text>
</graphic>
</fig>
</sec>
</sec>
<sec id="s4">
<title>4 Discussion</title>
<p>According to the Tibetan medicine classics such as &#x201c;Four Medical Classics&#x201d; (&#xf51;&#xf54;&#xf63;&#xf0b;&#x232;&#xf53;&#xf0b;&#x205;&#xf51;&#xf0b;&#xf56;&#xf5e;&#xf72;&#xf0d;) and &#x201c;Xin Xiu Jing Zhu Ben Cao&#x201d; (&#xf04;&#xf05;&#xf0d; &#xf0d; &#xf64;&#xf7a;&#xf63;&#xf0b;&#xf42;&#xf7c;&#xf44;&#xf0b;&#xf64;&#xf7a;&#xf63;&#xf0b;&#xf7a;&#xf44;&#xf0b;&#xf42;&#xf66;&#xf62;&#xf0b;&#xf56;&#x20c;&#xf72;&#xf42;&#xf66;&#xf0d; &#xf0d;), <italic>S. moorcroftiana</italic> seeds have traditional uses in treating jaundice, hepatitis, purulent tonsillitis, diphtheria, and parasitic diseases. These seeds have been found to possess inhibitory effects on liver fibrosis (<xref ref-type="bibr" rid="B27">Min et al., 2018</xref>), protective effects against acute pneumonia (<xref ref-type="bibr" rid="B44">Xu et al., 2023</xref>), and anti-parasitic effects (<xref ref-type="bibr" rid="B25">Luo Y. et al., 2018</xref>). In our previous research, SMS increased the viability of t-BHP-induced HepG2 cells and may play a protective role in liver by inhibiting oxidative stress through MAPK pathway (<xref ref-type="bibr" rid="B48">Yuan et al., 2022</xref>).</p>
<p>In our previous research, sophocarpine, matrine, oxymatrine, and oxysophocarpine were isolated and identified from <italic>S. moorcroftiana</italic> extract (<xref ref-type="bibr" rid="B47">Yuan et al., 2016</xref>). The presence of alkaloid components was additionally verified using LC-MS (<xref ref-type="bibr" rid="B48">Yuan et al., 2022</xref>). This study involved quantifying the levels of sophocarpine, matrine, oxymatrine, and oxysophocarpine through HPLC analysis (<xref ref-type="fig" rid="F1">Figures 1A,B</xref>). Previous studies have potential benefits of these compounds: sophocarpine for improving lipid metabolism and reducing inflammation and steatosis (<xref ref-type="bibr" rid="B37">Song et al., 2011</xref>; <xref ref-type="bibr" rid="B52">Zhang et al., 2020</xref>), matrine for significantly mitigating liver inflammation and lipid peroxidation by modulating endoplasmic reticulum stress and restoring mitochondrial function (<xref ref-type="bibr" rid="B11">Gao et al., 2018</xref>), oxymatrine for ameliorating liver fat accumulation in NAFLD models (<xref ref-type="bibr" rid="B52">Zhang et al., 2020</xref>), and oxysophocarpine exhibits effects in improving oxidative stress and inflammation factors in mice with colitis (<xref ref-type="bibr" rid="B24">Liu et al., 2023</xref>).</p>
<p>NAFLD is a common chronic liver disease and a serious pathological process characterized by fat accumulation in the liver, leading to NASH or hepatocellular carcinoma (<xref ref-type="bibr" rid="B4">Bedossa, 2017</xref>; <xref ref-type="bibr" rid="B10">Friedman et al., 2018</xref>). The pathological progression of NAFLD is closely related to lipid accumulation, oxidative stress and inflammation (<xref ref-type="bibr" rid="B6">Cobbina and Akhlaghi, 2017</xref>; <xref ref-type="bibr" rid="B5">Chen et al., 2020</xref>). NAFLD is caused by increased accumulation of TC and TG in the liver (<xref ref-type="bibr" rid="B41">Wang et al., 2021</xref>) Silymarin can regulate energy metabolism, attenuate liver damage, and improve liver histology in NAFLD patients (<xref ref-type="bibr" rid="B19">Li et al., 2024</xref>) Currently, T2M drugs are mainly used in the treatment of NAFLD, including Liraglutide, Semaglutide, Dapagliflozin (<xref ref-type="bibr" rid="B31">Rong et al., 2023</xref>). The levels of serum TC, TG, ALT, and AST confirm the establishment of the model groups. TC, TG, LDL-C and HDL-C were decreased compare with HFD group (<xref ref-type="fig" rid="F2">Figures 2A&#x2013;F</xref>), And SMS effectively inhibits lipid accumulation. MDA is the most common marker of oxidative stress. NAFLD is accompanied by increased MDA activity and decreased antioxidant levels (CAT, SOD, and GSH-Px) (<xref ref-type="bibr" rid="B16">Korish and Arafah, 2013</xref>; <xref ref-type="bibr" rid="B5">Chen et al., 2020</xref>). This experiment suggests that SMS effectively improves NAFLD lesions by inhibiting oxidative stress, reducing MDA activity, and increasing the levels of SOD and GSH-Px (<xref ref-type="fig" rid="F4">Figures 4A&#x2013;C</xref>), Inflammation factors such as TNF-&#x3b1; and IL-1&#x3b2; play a crucial role in the pathogenesis of NAFLD (<xref ref-type="bibr" rid="B28">Mirea et al., 2018</xref>; <xref ref-type="bibr" rid="B39">Vachliotis and Polyzos, 2023</xref>). SMS decreased the expression levels of inflammatory factors such as TNF-&#x3b1;, IL-6, IL-18, and IL-1&#x3b2; in HFD-fed C57BL/6J mice (<xref ref-type="fig" rid="F4">Figures 4D&#x2013;G</xref>).</p>
<p>The lipid accumulation model induced by FFA in HepG2 cells is commonly utilized for NAFLD research <italic>in vitro</italic> (<xref ref-type="bibr" rid="B30">Park et al., 2019</xref>). In comparison to the control group, treatment with SMS significantly decreased TC, TG, and LDL-C levels while increasing high-density lipoprotein cholesterol HDL-C levels (<xref ref-type="fig" rid="F6">Figures 6B&#x2013;E</xref>), indicating a reduction in lipid accumulation. Moreover, SMS treatment led to lower levels of ROS, MDA, CAT, SOD, and GSH-Px, suggesting a decline in oxidative stress (<xref ref-type="fig" rid="F7">Figures 7A&#x2013;E</xref>). Additionally, SMS treatment resulted in decreased levels of TNF-&#x3b1;, IL-6, IL-18, and IL-1&#x3b2;, indicating a reduction in inflammation (<xref ref-type="fig" rid="F7">Figures 7F&#x2013;I</xref>). This study demonstrates that SMS can effectively reduce lipid accumulation, oxidative stress, and inflammation in both NAFLD mice and cellular models of lipid accumulation.</p>
<p>Pyroptosis represents a distinct type of programmed cell death, characterized by membrane pores that lead to cell rupture, in contrast to apoptosis, which does not involve the cell membrane (<xref ref-type="bibr" rid="B40">Wang et al., 2020</xref>). Pyroptosis, gut microbiota, autophagy, apoptosis are the cause of NAFLD (<xref ref-type="bibr" rid="B20">Lian et al., 2020</xref>; <xref ref-type="bibr" rid="B15">Huang et al., 2023</xref>). The administration of SMS resulted in a reduction in the number of membrane pores (<xref ref-type="fig" rid="F8">Figure 8B</xref>). LDH expression levels are commonly utilized to assess pyroptosis (<xref ref-type="bibr" rid="B43">Xu et al., 2021</xref>), and following SMS treatment, LDH levels were diminished. Pyroptosis in triggering the release of pro-inflammatory cytokines as part of the innate immune response (<xref ref-type="bibr" rid="B42">Xu et al., 2018</xref>). The study findings indicate that SMS decreased the expression levels of inflammatory markers such as TNF-&#x3b1;, IL-6, IL-18, and IL-1&#x3b2; <italic>in vitro</italic>, with consistent results observed <italic>in vivo</italic> studies (<xref ref-type="fig" rid="F7">Figures 7F&#x2013;I, 4E&#x2013;H</xref>).</p>
<p>GSDMD is a protein that drives the execution of pyroptosis. Upon activation, GSDMD is cleaved into GSDMD-N fragments, which subsequently create pores in the cell membrane (<xref ref-type="bibr" rid="B18">Li S. et al., 2021</xref>). This cascade triggers the release of inflammatory factors, ultimately resulting in cell death. The activation of GSDMD is intricately linked with the activation of the NLRP3 inflammasome (<xref ref-type="bibr" rid="B54">Zheng and Kanneganti, 2020</xref>; <xref ref-type="bibr" rid="B45">Yan et al., 2021</xref>), crucial for caspase 1-dependent pyroptosis. NLRP3 activation enhances caspase 1 cleavage by facilitating interactions between ASC and NLRP3 inflammasome domains (<xref ref-type="bibr" rid="B1">Aachoui et al., 2013</xref>; <xref ref-type="bibr" rid="B7">Elliott and Sutterwala, 2015</xref>; <xref ref-type="bibr" rid="B38">Sun et al., 2019</xref>). Furthermore, it promotes the maturation of IL-1&#x3b2; and IL-18, initiating an inflammatory response (<xref ref-type="bibr" rid="B46">Yoshihara et al., 2014</xref>). Cleaved caspase 1 targets GSDMD, resulting in GSDMD-N translocation to the inner leaflet of the plasma membrane, where oligomerization occurs, forming membrane pores (<xref ref-type="bibr" rid="B23">Liu et al., 2022</xref>). In this study, SMS was shown to inhibit NLRP3 inflammasome activation, reduce NLRP3 protein levels, and attenuate caspase 1 activity in free fatty acid-treated HepG2 cells and high-fat diet-fed mice livers. In summary, the findings suggest that SMS can suppress NLRP3/GSDMD protein expression, potentially ameliorating NAFLD by inhibiting pyroptosis.</p>
<p>TXNIP is a widely distributed protein that acts as an inhibitor of TRX, an oxidoreductase responsible for reducing oxidized proteins and scavenging free radicals. In individuals with diabetes or prediabetes, TXNIP expression is elevated (<xref ref-type="bibr" rid="B29">Muoio, 2007</xref>). Moreover, increased TXNIP expression is observed in NAFLD (<xref ref-type="bibr" rid="B55">Zheng et al., 2018</xref>; <xref ref-type="bibr" rid="B13">Guo et al., 2022</xref>). The release of TXNIP from TRX triggers the activation of NLRP3 (<xref ref-type="bibr" rid="B56">Zhou et al., 2010</xref>). Following siRNA-TXNIP treatment, a notable decrease in inflammatory factors and lipid accumulation levels, along with reduced LDH expression levels, was observed, suggesting that TXNIP could be a promising target for SMS in combating free fatty acid-induced pyroptosis in HepG2 cells. ROS significantly contribute to the pathogenesis of NAFLD, exacerbating its progression. ROS have long been recognized as key players in various cell death modalities, including pyroptosis, apoptosis, and necroptosis (<xref ref-type="bibr" rid="B2">Anania et al., 2018</xref>; <xref ref-type="bibr" rid="B9">Farzanegi et al., 2019</xref>). ROS generation can oxidize TRX, causing the dissociation of TXNIP from TRX (<xref ref-type="bibr" rid="B56">Zhou et al., 2010</xref>). Notably, experiments revealed that treatment with SMS markedly reduced ROS levels in FFA-induced HepG2 cells impacting TXNIP expression <italic>in vitro</italic> (<xref ref-type="fig" rid="F3">Figure 3A</xref>).</p>
<p>In conclusion, our research findings indicate that SMS alleviates lipid accumulation, oxidative stress, and inflammation in NAFLD by inhibiting the ROS/TXNIP/NLRP3-mediated pyroptosis pathway (<xref ref-type="fig" rid="F11">Figure 11</xref>). Thus, SMS could offer novel insights and approaches for NAFLD treatment. <italic>S. moorcroftiana</italic> showed potential value in the treatment of NAFLD, which can transform into NASH and liver fibrosis, and further studies on liver diseases will be conducted in subsequent studies.</p>
<fig id="F11" position="float">
<label>FIGURE 11</label>
<caption>
<p>A schematic diagram representing that SMS <italic>via</italic> regulates NLRP3 inflammasome activation and pyroptosis <italic>via</italic> ROS/TXNIP pathway contributes to amelioration NAFLD.</p>
</caption>
<graphic xlink:href="fphar-16-1622178-g011.tif">
<alt-text content-type="machine-generated">Illustration of a biochemical process involving SMS (Schisandra chinensis), which inhibits the formation of ROS and affects the NLRP3 inflammasome complex. The pathway includes TXNIP activation, leading to caspase-1 cleavage and the release of inflammatory cytokines like IL-18 and IL-1&#x3B2;, initiating pyroptosis and inflammation. Two inset images show Schisandra chinensis seeds and flowers.</alt-text>
</graphic>
</fig>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s12">Supplementary Material</xref>, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec sec-type="ethics-statement" id="s6">
<title>Ethics statement</title>
<p>The animal study was approved by Qingdao University of Science and Technology. The study was conducted in accordance with the local legislation and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>RY: Methodology, Writing &#x2013; original draft. MG: Methodology, Writing &#x2013; original draft. SH: Methodology, Writing &#x2013; review and editing. YC: Methodology, Writing &#x2013; review and editing. DZ: Data curation, Writing &#x2013; review and editing. GY: Methodology, Writing &#x2013; review and editing. WZ: Writing &#x2013; review and editing, Methodology. SW: Funding acquisition, Writing &#x2013; review and editing. BL: Funding acquisition, Writing &#x2013; original draft.</p>
</sec>
<sec sec-type="funding-information" id="s8">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by grants from the Central Guided Local Science and Technology Development Project (Free Exploration Basic Research) (XZ202301YD0016C), Science and Technology Program of Lhasa, Tibet Autonomous Region (LSKJ202321), National Natural Science Foundation of China (U24A20796, 81960781) and Tibet University Graduate Student High-Level Talent Cultivation Program (2022-GSP-S125).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s10">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="s12">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fphar.2025.1622178/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fphar.2025.1622178/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/docx" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aachoui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sagulenko</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Stacey</surname>
<given-names>K. J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection</article-title>. <source>Curr. Opin. Microbiol.</source> <volume>16</volume>, <fpage>319</fpage>&#x2013;<lpage>326</lpage>. <pub-id pub-id-type="doi">10.1016/j.mib.2013.04.004</pub-id>
<pub-id pub-id-type="pmid">23707339</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anania</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Perla</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Olivero</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pacifico</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chiesa</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mediterranean diet and nonalcoholic fatty liver disease</article-title>. <source>World J. Gastroenterol.</source> <volume>24</volume>, <fpage>2083</fpage>&#x2013;<lpage>2094</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v24.i19.2083</pub-id>
<pub-id pub-id-type="pmid">29785077</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arrese</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cabrera</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kalergis</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Feldstein</surname>
<given-names>A. E.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Innate immunity and inflammation in NAFLD/NASH</article-title>. <source>Dig. Dis. Sci.</source> <volume>61</volume>, <fpage>1294</fpage>&#x2013;<lpage>1303</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-016-4049-x</pub-id>
<pub-id pub-id-type="pmid">26841783</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedossa</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pathology of non-alcoholic fatty liver disease</article-title>. <source>Liver Int.</source> <volume>37</volume>, <fpage>85</fpage>&#x2013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1111/liv.13301</pub-id>
<pub-id pub-id-type="pmid">28052629</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>She</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease</article-title>. <source>Free Radic. Biol. Med.</source> <volume>152</volume>, <fpage>116</fpage>&#x2013;<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2020.02.025</pub-id>
<pub-id pub-id-type="pmid">32156524</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cobbina</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Akhlaghi</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Non-alcoholic fatty liver disease (NAFLD) &#x2013; pathogenesis, classification, and effect on drug metabolizing enzymes and transporters</article-title>. <source>Drug Metab. Rev.</source> <volume>49</volume>, <fpage>197</fpage>&#x2013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1080/03602532.2017.1293683</pub-id>
<pub-id pub-id-type="pmid">28303724</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elliott</surname>
<given-names>E. I.</given-names>
</name>
<name>
<surname>Sutterwala</surname>
<given-names>F. S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Initiation and perpetuation of NLRP 3 inflammasome activation and assembly</article-title>. <source>Immunol. Rev.</source> <volume>265</volume>, <fpage>35</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12286</pub-id>
<pub-id pub-id-type="pmid">25879282</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ezquerro</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mocha</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fr&#xfc;hbeck</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guzm&#xe1;n-Ruiz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Valent&#xed;</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Mugueta</surname>
<given-names>C.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Ghrelin reduces TNF-&#x3b1;-induced human hepatocyte apoptosis, autophagy and pyroptosis: role in obesity-associated NAFLD</article-title>. <source>J. Clin. Endocrinol. Metab.</source> <volume>104</volume>, <fpage>21</fpage>&#x2013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2018-01171</pub-id>
<pub-id pub-id-type="pmid">30137403</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farzanegi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dana</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ebrahimpoor</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Asadi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Azarbayjani</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation</article-title>. <source>Eur. J. Sport Sci.</source> <volume>19</volume>, <fpage>994</fpage>&#x2013;<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1080/17461391.2019.1571114</pub-id>
<pub-id pub-id-type="pmid">30732555</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Neuschwander-Tetri</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Rinella</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sanyal</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mechanisms of NAFLD development and therapeutic strategies</article-title>. <source>Nat. Med.</source> <volume>24</volume>, <fpage>908</fpage>&#x2013;<lpage>922</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0104-9</pub-id>
<pub-id pub-id-type="pmid">29967350</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Matrine attenuates endoplasmic reticulum stress and mitochondrion dysfunction in nonalcoholic fatty liver disease by regulating SERCA pathway</article-title>. <source>J. Transl. Med.</source> <volume>16</volume>, <fpage>319</fpage>. <pub-id pub-id-type="doi">10.1186/s12967-018-1685-2</pub-id>
<pub-id pub-id-type="pmid">30458883</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaul</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Leszczynska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alegre</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>C. D.</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>L. A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis</article-title>. <source>J. Hepatol.</source> <volume>74</volume>, <fpage>156</fpage>&#x2013;<lpage>167</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2020.07.041</pub-id>
<pub-id pub-id-type="pmid">32763266</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Association of circulating TXNIP levels with fatty liver in newly diagnosed type 2 diabetes mellitus</article-title>. <source>Diabetes Metab. Syndr. Obes. Targets Ther.</source> <volume>15</volume>, <fpage>225</fpage>&#x2013;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.2147/DMSO.S349153</pub-id>
<pub-id pub-id-type="pmid">35115798</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Optimization of supercritical-CO2 extraction and pharmacokinetics in SD rats of alkaloids form Sophora moorcroftiana seed</article-title>. <source>Sci. Rep.</source> <volume>12</volume>, <fpage>3301</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-022-07278-1</pub-id>
<pub-id pub-id-type="pmid">35228632</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Canagliflozin ameliorates the development of NAFLD by preventing NLRP3-mediated pyroptosis through FGF21-ERK1/2 pathway</article-title>. <source>Hepatol. Commun.</source> <volume>7</volume>, <fpage>e0045</fpage>. <pub-id pub-id-type="doi">10.1097/HC9.0000000000000045</pub-id>
<pub-id pub-id-type="pmid">36757426</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Korish</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Arafah</surname>
<given-names>M. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Camel milk ameliorates steatohepatitis, insulin resistance and lipid peroxidation in experimental non-alcoholic fatty liver disease</article-title>. <source>BMC Complement. Altern. Med.</source> <volume>13</volume>, <fpage>264</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6882-13-264</pub-id>
<pub-id pub-id-type="pmid">24119413</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hesperetin ameliorates hepatic oxidative stress and inflammation <italic>via</italic> the PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD</article-title>. <source>Food Funct.</source> <volume>12</volume>, <fpage>3898</fpage>&#x2013;<lpage>3918</lpage>. <pub-id pub-id-type="doi">10.1039/D0FO02736G</pub-id>
<pub-id pub-id-type="pmid">33977953</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>NLRP3/caspase-1/GSDMD&#x2013;mediated pyroptosis exerts a crucial role in astrocyte pathological injury in mouse model of depression</article-title>. <source>JCI Insight</source> <volume>6</volume>, <fpage>e146852</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.146852</pub-id>
<pub-id pub-id-type="pmid">34877938</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Administration of silymarin in NAFLD/NASH: a systematic review and meta-analysis</article-title>. <source>Ann. Hepatol.</source> <volume>29</volume>, <fpage>101174</fpage>. <pub-id pub-id-type="doi">10.1016/j.aohep.2023.101174</pub-id>
<pub-id pub-id-type="pmid">38579127</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lian</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Zhai</surname>
<given-names>Z.-Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.-F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>High fat diet-triggered non-alcoholic fatty liver disease: a review of proposed mechanisms</article-title>. <source>Chem. Biol. Interact.</source> <volume>330</volume>, <fpage>109199</fpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2020.109199</pub-id>
<pub-id pub-id-type="pmid">32805210</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.-M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>A.-M.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.-L.</given-names>
</name>
<name>
<surname>L&#xf3;pez-Pujol</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Genetic diversity, population structure, and conservation of Sophora moorcroftiana (fabaceae), a shrub endemic to the Tibetan Plateau</article-title>. <source>Plant Biol.</source> <volume>8</volume>, <fpage>81</fpage>&#x2013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1055/s-2005-872889</pub-id>
<pub-id pub-id-type="pmid">16435272</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ruan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Magupalli</surname>
<given-names>V. G.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores</article-title>. <source>Nature</source> <volume>535</volume>, <fpage>153</fpage>&#x2013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1038/nature18629</pub-id>
<pub-id pub-id-type="pmid">27383986</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Cold stress induced liver injury of mice through activated NLRP3/Caspase-1/GSDMD pyroptosis signaling pathway</article-title>. <source>Biomolecules</source> <volume>12</volume>, <fpage>927</fpage>. <pub-id pub-id-type="doi">10.3390/biom12070927</pub-id>
<pub-id pub-id-type="pmid">35883482</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Oxysophocarpine suppresses TRAF6 level to ameliorate oxidative stress and inflammatory factors secretion in mice with dextran sulphate sodium (DSS) induced-ulcerative colitis</article-title>. <source>Microb. Pathog.</source> <volume>182</volume>, <fpage>106244</fpage>. <pub-id pub-id-type="doi">10.1016/j.micpath.2023.106244</pub-id>
<pub-id pub-id-type="pmid">37423495</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Therapeutic and immunoregulatory effects of water-soluble alkaloids E2-a from Sophora moorcroftiana seeds as a novel potential agent against echinococcosis in experimentally protoscolex-infected mice</article-title>. <source>Vet. Res.</source> <volume>49</volume>, <fpage>100</fpage>. <pub-id pub-id-type="doi">10.1186/s13567-018-0596-9</pub-id>
<pub-id pub-id-type="pmid">30286809</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname>
<given-names>Y.-P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.-M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.-J.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Anti-parasitic effects of water-soluble alkaloid fractions from ethanolic extracts of Sophora moorcroftiana seeds in <italic>Caenorhabditis elegans</italic>
</article-title>. <source>Chin. J. Nat. Med.</source> <volume>16</volume>, <fpage>665</fpage>&#x2013;<lpage>673</lpage>. <pub-id pub-id-type="doi">10.1016/S1875-5364(18)30106-7</pub-id>
<pub-id pub-id-type="pmid">30269843</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Min</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Optimization of extraction technology of total alkaloids from Sophora moorcroftiana based on multi index comprehensive detection and its mechanism of anti-hepatic fibrosis</article-title>. <source>Guid. J. Tradit. Chin. Med. Pharm.</source> <volume>24</volume>, <fpage>14</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.13862/j.cnki.cn43-1446/r.2018.10.003</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirea</surname>
<given-names>A.-M.</given-names>
</name>
<name>
<surname>Tack</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Chavakis</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Joosten</surname>
<given-names>L. A. B.</given-names>
</name>
<name>
<surname>Toonen</surname>
<given-names>E. J. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>IL-1 family cytokine pathways underlying NAFLD: towards new treatment strategies</article-title>. <source>Trends Mol. Med.</source> <volume>24</volume>, <fpage>458</fpage>&#x2013;<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2018.03.005</pub-id>
<pub-id pub-id-type="pmid">29665983</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muoio</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>TXNIP links redox circuitry to glucose control</article-title>. <source>Cell Metab.</source> <volume>5</volume>, <fpage>412</fpage>&#x2013;<lpage>414</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmet.2007.05.011</pub-id>
<pub-id pub-id-type="pmid">17550776</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.-S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.-J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Lonicera caerulea extract attenuates Non-Alcoholic fatty liver disease in free fatty acid-induced HepG2 hepatocytes and in high fat diet-fed mice</article-title>. <source>Nutrients</source> <volume>11</volume>, <fpage>494</fpage>. <pub-id pub-id-type="doi">10.3390/nu11030494</pub-id>
<pub-id pub-id-type="pmid">30813654</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ran</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)</article-title>. <source>Front. Endocrinol.</source> <volume>13</volume>, <fpage>1087260</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.1087260</pub-id>
<pub-id pub-id-type="pmid">36726464</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3</article-title>. <source>Int. Immunopharmacol.</source> <volume>100</volume>, <fpage>108126</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2021.108126</pub-id>
<pub-id pub-id-type="pmid">34492534</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Serviddio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bellanti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Vendemiale</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Free radical biology for medicine: learning from nonalcoholic fatty liver disease</article-title>. <source>Free Radic. Biol. Med.</source> <volume>65</volume>, <fpage>952</fpage>&#x2013;<lpage>968</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2013.08.174</pub-id>
<pub-id pub-id-type="pmid">23994574</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title>. <source>Nature</source> <volume>526</volume>, <fpage>660</fpage>&#x2013;<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1038/nature15514</pub-id>
<pub-id pub-id-type="pmid">26375003</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Pyroptosis: Gasdermin-mediated programmed necrotic cell death</article-title>. <source>Trends biochem. Sci.</source> <volume>42</volume>, <fpage>245</fpage>&#x2013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2016.10.004</pub-id>
<pub-id pub-id-type="pmid">27932073</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirataki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yokoe</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tomimori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Komatsu</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1988</year>). <article-title>Studies on the constituents of Sophora species. XXII. Constituents of the root of Sophora moorcroftiana BENTH. ex BAKER.(1)</article-title>. <source>Chem. Pharm. Bull. (Tokyo)</source> <volume>36</volume>, <fpage>2220</fpage>&#x2013;<lpage>2225</lpage>. <pub-id pub-id-type="doi">10.1248/cpb.36.2220</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.-W.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>P.-F.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Z.-W.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>B.-F.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Sophocarpine alleviates non-alcoholic steatohepatitis in rats</article-title>. <source>J. Gastroenterol. Hepatol.</source> <volume>26</volume>, <fpage>765</fpage>&#x2013;<lpage>774</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1746.2010.06561.x</pub-id>
<pub-id pub-id-type="pmid">21054517</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome</article-title>. <source>Cell Death Dis.</source> <volume>10</volume>, <fpage>542</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-019-1761-4</pub-id>
<pub-id pub-id-type="pmid">31316052</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vachliotis</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Polyzos</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic Fatty liver disease</article-title>. <source>Curr. Obes. Rep.</source> <volume>12</volume>, <fpage>191</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1007/s13679-023-00519-y</pub-id>
<pub-id pub-id-type="pmid">37407724</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Mechanistic differences in cell death responses to metal&#x2010;based engineered nanomaterials in kupffer cells and hepatocytes</article-title>. <source>Small</source> <volume>16</volume>, <fpage>2000528</fpage>. <pub-id pub-id-type="doi">10.1002/smll.202000528</pub-id>
<pub-id pub-id-type="pmid">32337854</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism</article-title>. <source>J. Adv. Res.</source> <volume>34</volume>, <fpage>109</fpage>&#x2013;<lpage>122</lpage>. <pub-id pub-id-type="doi">10.1016/j.jare.2021.06.001</pub-id>
<pub-id pub-id-type="pmid">35024184</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice</article-title>. <source>J. Hepatol.</source> <volume>68</volume>, <fpage>773</fpage>&#x2013;<lpage>782</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2017.11.040</pub-id>
<pub-id pub-id-type="pmid">29273476</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-&#x3ba;B/NLRP3 pathway</article-title>. <source>Atherosclerosis</source> <volume>317</volume>, <fpage>1</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2020.11.021</pub-id>
<pub-id pub-id-type="pmid">33321327</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Protective effect of Sophora moorcroftiana Alkaloid on LPS-induced acute pneumonia in mice</article-title>. <source>Prog. Vet. Med.</source> <volume>44</volume>, <fpage>59</fpage>&#x2013;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.16437/j.cnki.1007-5038.2023.08.012</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer</article-title>. <source>Int. J. Biol. Sci.</source> <volume>17</volume>, <fpage>2606</fpage>&#x2013;<lpage>2621</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.60292</pub-id>
<pub-id pub-id-type="pmid">34326697</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshihara</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Masaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yodoi</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Thioredoxin/Txnip: redoxisome, as a redox switch for the pathogenesis of diseases</article-title>. <source>Front. Immunol.</source> <volume>4</volume>, <fpage>514</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2013.00514</pub-id>
<pub-id pub-id-type="pmid">24409188</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Study on chemical constituents of Sophora moorcroftiana</article-title>. <source>J. Tibet. Univ.</source> <volume>31</volume>, <fpage>73</fpage>&#x2013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.16249/j.cnki.54-1034/c.2016.02.011</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dongzhi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Hepatoprotective effect of <italic>sophora M</italic> oorcroftiana (benth.) Benth.Ex baker seeds <italic>in vivo</italic> and <italic>in vitro</italic>
</article-title>. <source>Drug Chem. Toxicol.</source> <volume>45</volume>, <fpage>2535</fpage>&#x2013;<lpage>2544</lpage>. <pub-id pub-id-type="doi">10.1080/01480545.2021.1962692</pub-id>
<pub-id pub-id-type="pmid">34380357</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.-H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.-Y.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Q.-H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.-X.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Reactive oxygen species-induced TXNIP drives fructose-mediated hepatic inflammation and lipid accumulation through NLRP3 inflammasome activation</article-title>. <source>Antioxid. Redox Signal.</source> <volume>22</volume>, <fpage>848</fpage>&#x2013;<lpage>870</lpage>. <pub-id pub-id-type="doi">10.1089/ars.2014.5868</pub-id>
<pub-id pub-id-type="pmid">25602171</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>The investigation of the effect and mechanism of <italic>Sophora moorcroftiana</italic> alkaloids in combination with albendazole on echinococcosis in an experimental rats model</article-title>. <source>Evid. Based Complement. Altern. Med.</source> <volume>2018</volume>, <fpage>3523126</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1155/2018/3523126</pub-id>
<pub-id pub-id-type="pmid">29785189</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mi</surname>
<given-names>D.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.-P.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Constituent and effects of polysaccharides isolated from Sophora moorcroftiana seeds on lifespan, reproduction, stress resistance, and antimicrobial capacity in Caenorhabditis elegans</article-title>. <source>Chin. J. Nat. Med.</source> <volume>16</volume>, <fpage>252</fpage>&#x2013;<lpage>260</lpage>. <pub-id pub-id-type="doi">10.1016/S1875-5364(18)30055-4</pub-id>
<pub-id pub-id-type="pmid">29703325</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease</article-title>. <source>Life Sci.</source> <volume>257</volume>, <fpage>118090</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.118090</pub-id>
<pub-id pub-id-type="pmid">32679144</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>The role of autophagy and pyroptosis in liver disorders</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume>, <fpage>6208</fpage>. <pub-id pub-id-type="doi">10.3390/ijms23116208</pub-id>
<pub-id pub-id-type="pmid">35682887</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kanneganti</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The regulation of the ZBP1&#x2010;NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis)</article-title>. <source>Immunol. Rev.</source> <volume>297</volume>, <fpage>26</fpage>&#x2013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12909</pub-id>
<pub-id pub-id-type="pmid">32729116</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Salidroside attenuates high-fat diet-induced nonalcoholic fatty liver disease via AMPK-dependent TXNIP/NLRP3 pathway</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2018</volume>, <fpage>8597897</fpage>. <pub-id pub-id-type="doi">10.1155/2018/8597897</pub-id>
<pub-id pub-id-type="pmid">30140371</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tardivel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thorens</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tschopp</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Thioredoxin-interacting protein links oxidative stress to inflammasome activation</article-title>. <source>Nat. Immunol.</source> <volume>11</volume>, <fpage>136</fpage>&#x2013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1038/ni.1831</pub-id>
<pub-id pub-id-type="pmid">20023662</pub-id>
</citation>
</ref>
</ref-list>
<sec id="s13">
<title>Glossary</title>
<def-list>
<def-item>
<term id="G1-fphar.2025.1622178">
<bold>AKP</bold>
</term>
<def>
<p>Alkaline phosphatase</p>
</def>
</def-item>
<def-item>
<term id="G2-fphar.2025.1622178">
<bold>ALT</bold>
</term>
<def>
<p>Alanine aminotransferase</p>
</def>
</def-item>
<def-item>
<term id="G3-fphar.2025.1622178">
<bold>ASC</bold>
</term>
<def>
<p>Apoptosis associated speck-like protein containing a caspase recruitment domain</p>
</def>
</def-item>
<def-item>
<term id="G4-fphar.2025.1622178">
<bold>AST</bold>
</term>
<def>
<p>Aspartate aminotransferase</p>
</def>
</def-item>
<def-item>
<term id="G5-fphar.2025.1622178">
<bold>CAT</bold>
</term>
<def>
<p>Catalase</p>
</def>
</def-item>
<def-item>
<term id="G6-fphar.2025.1622178">
<bold>DMSO</bold>
</term>
<def>
<p>Dimethyl sulfoxide</p>
</def>
</def-item>
<def-item>
<term id="G7-fphar.2025.1622178">
<bold>ECL</bold>
</term>
<def>
<p>Enhanced chemiluminescence kit</p>
</def>
</def-item>
<def-item>
<term id="G8-fphar.2025.1622178">
<bold>ELISA</bold>
</term>
<def>
<p>Enzyme-linked immunosorbent assay</p>
</def>
</def-item>
<def-item>
<term id="G9-fphar.2025.1622178">
<bold>FBS</bold>
</term>
<def>
<p>Fetal bovine serum</p>
</def>
</def-item>
<def-item>
<term id="G10-fphar.2025.1622178">
<bold>FFA</bold>
</term>
<def>
<p>Free fatty acid</p>
</def>
</def-item>
<def-item>
<term id="G11-fphar.2025.1622178">
<bold>GSDMD</bold>
</term>
<def>
<p>Gasdermin D</p>
</def>
</def-item>
<def-item>
<term id="G12-fphar.2025.1622178">
<bold>GSH-PX</bold>
</term>
<def>
<p>Glutathione peroxidase</p>
</def>
</def-item>
<def-item>
<term id="G13-fphar.2025.1622178">
<bold>H&#x26;E staining</bold>
</term>
<def>
<p>Hematoxylin eosin staining</p>
</def>
</def-item>
<def-item>
<term id="G14-fphar.2025.1622178">
<bold>HDL-C</bold>
</term>
<def>
<p>High-density lipoprotein cholesterol</p>
</def>
</def-item>
<def-item>
<term id="G15-fphar.2025.1622178">
<bold>HPLC</bold>
</term>
<def>
<p>High performance liquid chromatography</p>
</def>
</def-item>
<def-item>
<term id="G16-fphar.2025.1622178">
<bold>IgG</bold>
</term>
<def>
<p>Immunoglobulin G</p>
</def>
</def-item>
<def-item>
<term id="G17-fphar.2025.1622178">
<bold>IL-18</bold>
</term>
<def>
<p>Interleukin-18</p>
</def>
</def-item>
<def-item>
<term id="G18-fphar.2025.1622178">
<bold>IL-1&#x3b2;</bold>
</term>
<def>
<p>Interleukin-1&#x3b2;</p>
</def>
</def-item>
<def-item>
<term id="G19-fphar.2025.1622178">
<bold>LDH</bold>
</term>
<def>
<p>Lactate dehydrogenase</p>
</def>
</def-item>
<def-item>
<term id="G20-fphar.2025.1622178">
<bold>LDL-C</bold>
</term>
<def>
<p>Low-density lipoprotein cholesterol</p>
</def>
</def-item>
<def-item>
<term id="G21-fphar.2025.1622178">
<bold>MDA</bold>
</term>
<def>
<p>Malondialdehyde</p>
</def>
</def-item>
<def-item>
<term id="G22-fphar.2025.1622178">
<bold>MEM</bold>
</term>
<def>
<p>Minimum essential medium</p>
</def>
</def-item>
<def-item>
<term id="G23-fphar.2025.1622178">
<bold>MTT</bold>
</term>
<def>
<p>3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide</p>
</def>
</def-item>
<def-item>
<term id="G24-fphar.2025.1622178">
<bold>NAFLD</bold>
</term>
<def>
<p>Non-Alcoholic Fatty Liver Diseas</p>
</def>
</def-item>
<def-item>
<term id="G25-fphar.2025.1622178">
<bold>NLRP3</bold>
</term>
<def>
<p>NOD-like receptor thermal protein domain associated protein 3</p>
</def>
</def-item>
<def-item>
<term id="G26-fphar.2025.1622178">
<bold>OD</bold>
</term>
<def>
<p>Optical density</p>
</def>
</def-item>
<def-item>
<term id="G27-fphar.2025.1622178">
<bold>P/S</bold>
</term>
<def>
<p>Penicillin/streptomycin</p>
</def>
</def-item>
<def-item>
<term id="G28-fphar.2025.1622178">
<bold>PMSF</bold>
</term>
<def>
<p>Phenylmethanesulfonyl fluoride</p>
</def>
</def-item>
<def-item>
<term id="G29-fphar.2025.1622178">
<bold>qRT-PCR</bold>
</term>
<def>
<p>Quantitative real-time polymerase chain reaction</p>
</def>
</def-item>
<def-item>
<term id="G30-fphar.2025.1622178">
<bold>RIPA</bold>
</term>
<def>
<p>Radioimmunoprecipitation lysis buffer</p>
</def>
</def-item>
<def-item>
<term id="G31-fphar.2025.1622178">
<bold>ROS</bold>
</term>
<def>
<p>Reactive oxygen species</p>
</def>
</def-item>
<def-item>
<term id="G32-fphar.2025.1622178">
<bold>SD</bold>
</term>
<def>
<p>Standard deviation</p>
</def>
</def-item>
<def-item>
<term id="G33-fphar.2025.1622178">
<bold>SDS-PAGE</bold>
</term>
<def>
<p>Sodium dodecyl sulfate-polyacrylamide gel electrophoresis</p>
</def>
</def-item>
<def-item>
<term id="G34-fphar.2025.1622178">
<bold>SEM</bold>
</term>
<def>
<p>Scanning electron microscopy</p>
</def>
</def-item>
<def-item>
<term id="G35-fphar.2025.1622178">
<bold>siRNA</bold>
</term>
<def>
<p>Small interfering RNA</p>
</def>
</def-item>
<def-item>
<term id="G36-fphar.2025.1622178">
<bold>SMS</bold>
</term>
<def>
<p>70% ethanol extract of <italic>S. moocroftiana</italic> seeds</p>
</def>
</def-item>
<def-item>
<term id="G37-fphar.2025.1622178">
<bold>SOD</bold>
</term>
<def>
<p>Superoxide dismutase</p>
</def>
</def-item>
<def-item>
<term id="G38-fphar.2025.1622178">
<bold>TC</bold>
</term>
<def>
<p>Total cholesterol</p>
</def>
</def-item>
<def-item>
<term id="G39-fphar.2025.1622178">
<bold>TG</bold>
</term>
<def>
<p>Triglyceride</p>
</def>
</def-item>
<def-item>
<term id="G40-fphar.2025.1622178">
<bold>TNF-&#x3b1;</bold>
</term>
<def>
<p>Tumor necrosis factor-&#x3b1;</p>
</def>
</def-item>
<def-item>
<term id="G41-fphar.2025.1622178">
<bold>TRX</bold>
</term>
<def>
<p>Thioredoxin</p>
</def>
</def-item>
<def-item>
<term id="G42-fphar.2025.1622178">
<bold>TXNIP</bold>
</term>
<def>
<p>Thioredoxin-interacting protein</p>
</def>
</def-item>
<def-item>
<term id="G43-fphar.2025.1622178">
<bold>WB</bold>
</term>
<def>
<p>Western blotting</p>
</def>
</def-item>
</def-list>
</sec>
</back>
</article>